Core Problem: Urolithin A (UroA) efficacy is bottlenecked by individual microbiome capacity for conversion from ellagitannins. Direct supplementation bypasses this but doesn't solve underlying inefficacy in tissues or non-responsive metabotypes. The dual-pathway activation (AMPK/ULK1 and PINK1/Parkin) offers redundancy, but pre-existing mitochondrial and transcriptional states likely determine the magnitude of response.

Hypothesis: Pre-exposure to the postbiotic butyrate establishes a permissive epigenetic and metabolic state in target tissues (e.g., skeletal muscle, liver), "priming" the AMPK-SIRT1-PINK1 axis. This priming lowers the activation threshold for UroA-induced mitophagy, effectively amplifying its effect in UroA non-producers or low-producers. The mechanism involves butyrate-induced histone acetylation at key mitophagy gene promoters and enhanced mitochondrial membrane depolarization sensitivity.

Novel Mechanistic Rationale:

1. Epigenetic Priming: Butyrate, a known histone deacetylase inhibitor (HDACi), could increase chromatin accessibility at loci for PINK1, PRKN (Parkin), ULK1, and BNIP3/NIX. This would create a transcriptionally "poised" state, allowing a sub-threshold UroA signal to trigger a robust mitophagic transcriptional program.
2. Metabolic Sensitization: Butyrate is an HDACi and a direct mitochondrial fuel, enhancing oxidative metabolism. Chronic low-level exposure could subtly increase mitochondrial membrane potential heterogeneity, generating a higher basal pool of depolarized mitochondria—the prime substrate for PINK1 stabilization. This "metabolic stress priming" would mean more targets are immediately available when UroA arrives.
3. SIRT1 as the Integrative Hub: Butyrate upregulates and activates SIRT1 via NAD+ modulation. SIRT1 deacetylates and activates PGC-1α (promoting mitochondrial biogenesis) and FOXO transcription factors. Critically, SIRT1 also directly deacetylates and activates PINK1 and AMPK. Thus, butyrate pre-treatment could elevate the activity of this entire regulatory node, creating a hyper-responsive state to UroA's AMPK-activating signal [https://doi.org/10.1080/15548627.2019.1586258].

Testable Predictions:

• In vitro: Pre-treating myotubes or hepatocytes with sodium butyrate (1-5 mM) for 24-48h will significantly enhance UroA (10-50 μM)-induced mitophagy flux (measured by mt-Keima or Mito-QC) compared to UroA alone, even in cell lines with low baseline PINK1 expression.
• Molecular: Butyrate pre-treatment will increase H3K9/K27 acetylation at PINK1 and PRKN promoters (ChIP-qPCR) and elevate SIRT1 protein/activity levels, correlating with enhanced PINK1 accumulation on depolarized mitochondria upon UroA challenge.
• In vivo (translation): In UroA "low-producer" humanized microbiota mice or stratified human cohorts, a 2-week dietary butyrate precursor (e.g., resistant starch) regimen will "prime" the system, leading to a 2-3 fold increase in mitophagy markers in PBMCs or muscle biopsies following a standardized UroA supplement, compared to UroA alone. This tests the core translational bypass.

Falsification Criteria: The hypothesis is falsified if butyrate pre-treatment: 1) fails to increase transcriptional or protein levels of key mitophagy components, 2) does not sensitize cells to sub-optimal UroA doses in functional mitophagy assays, or 3) shows no enhancement of UroA's effects in validated in vivo models of mitochondrial dysfunction.

This moves beyond simple supplementation, proposing an epigenetic/metabolic "pre-conditioning" strategy to overcome individual variability and maximize the geroscience potential of UroA.